Jump Financial LLC Acquires 3,967 Shares of Sarepta Therapeutics, Inc. $SRPT

Jump Financial LLC boosted its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 218.2% in the 1st quarter, Holdings Channel.com reports. The institutional investor owned 5,785 shares of the biotechnology company’s stock after buying an additional 3,967 shares during the period. Jump Financial LLC’s holdings in Sarepta Therapeutics were worth $369,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in SRPT. Byrne Asset Management LLC bought a new stake in Sarepta Therapeutics during the first quarter worth about $30,000. Center for Financial Planning Inc. bought a new stake in Sarepta Therapeutics during the first quarter worth about $31,000. Pandora Wealth Inc. bought a new stake in Sarepta Therapeutics during the first quarter worth about $45,000. Brooklyn Investment Group lifted its stake in Sarepta Therapeutics by 450.4% during the first quarter. Brooklyn Investment Group now owns 721 shares of the biotechnology company’s stock worth $46,000 after purchasing an additional 590 shares during the last quarter. Finally, UMB Bank n.a. lifted its stake in Sarepta Therapeutics by 53.0% during the first quarter. UMB Bank n.a. now owns 797 shares of the biotechnology company’s stock worth $51,000 after purchasing an additional 276 shares during the last quarter. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Stock Down 0.2%

Shares of NASDAQ:SRPT opened at $18.16 on Wednesday. Sarepta Therapeutics, Inc. has a 1 year low of $10.41 and a 1 year high of $138.81. The company has a market cap of $1.77 billion, a PE ratio of -20.87 and a beta of 0.49. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.89 and a quick ratio of 1.81. The stock’s 50-day moving average is $17.69 and its 200 day moving average is $45.76.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $2.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.89 by $1.13. Sarepta Therapeutics had a negative return on equity of 1.03% and a negative net margin of 2.34%.The company had revenue of $611.09 million for the quarter, compared to the consensus estimate of $530.66 million. During the same quarter in the previous year, the business earned $0.07 EPS. Sarepta Therapeutics’s revenue was up 68.4% compared to the same quarter last year. Sell-side analysts anticipate that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on SRPT shares. Piper Sandler lifted their price target on Sarepta Therapeutics to $15.00 and gave the stock a “neutral” rating in a research note on Tuesday, July 29th. The Goldman Sachs Group lifted their price target on Sarepta Therapeutics to $19.00 and gave the stock a “neutral” rating in a research note on Thursday, August 7th. Scotiabank raised Sarepta Therapeutics from a “sector perform” rating to a “sector outperform” rating and set a $80.00 price target for the company in a research note on Friday, June 6th. Citigroup started coverage on Sarepta Therapeutics in a report on Tuesday, July 22nd. They issued a “sell” rating on the stock. Finally, Bank of America lifted their price objective on Sarepta Therapeutics to $17.00 and gave the stock an “underperform” rating in a report on Wednesday, August 20th. Eight investment analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and six have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $43.50.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.